Recombinant Anti-CD47 × Anti-SIRPA Bispecific Antibody (Tandem Diabody) is a bispecific fusion protein with four binding sites, two of which bind to antigens of one kind of cells and the other two to the other kind of cells. Tandem Diabodies do not carry Fc domains. So they are smaller than whole IgGs or IgG-derived BsAbs but larger than tandem scFvs. Therefore, they have a shorter serum half-life than IgGs but remain longer in the circulation compared with tandem scFvs. This BsAb is capable of inhibiting signaling of their cognate factors and a combined blockade of them has a greater inhibitory efficacy compared with inhibition of either factor alone. It was designed for the treatment of breast cancer, non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML).

Specifications

Target

Target 1
CD47

Gene ID
961

UniProt ID
Q08722

Alternative Names
CD47; CD47 molecule; IAP; OA3; MER6; leukocyte surface antigen CD47; CD47 glycoprotein; Rh-related antigen; integrin associated protein; integrin-associated protein; integrin-associated signal transducer; antigenic surface determinant protein OA3; antigen

Target 2
SIRPA

Gene ID
140885

UniProt ID
P78324

Alternative Names
SIRPA; signal-regulatory protein alpha; BIT; MFR; P84; SIRP; MYD-1; SHPS1; CD172A; PTPNS1; tyrosine-protein phosphatase non-receptor type substrate 1; myd-1 antigen; inhibitory receptor SHPS-1; macrophage fusion receptor; CD172 antigen-like family member A; tyrosine phosphatase SHP substrate 1; brain-immunoglobulin-like molecule with tyrosine-based activation motifs

Downloads

Customer Reviews and Q&As